Modern Catalyst
The active pharmaceutical ingredient (API) manufacturing landscape is undergoing a structural realignment driven by geopolitical fragmentation and supply-chain vulnerability. As 2026 approaches, the traditional "make versus buy" calculus has fundamentally shifted. Pharmaceutical companies now weigh strategic control, risk tolerance, and regulatory readiness alongside cost—a departure from the cost-optimization mindset that dominated the 2010s.
The catalyst is twofold. First, global supply chains face sustained geopolitical pressure and raw material shortages, with API supply chains particularly exposed to disruption. Second, regulatory mandates—including U.S. Drug Supply Chain Security Act serialization, EU Falsified Medicines Directive compliance, and evolving Asia regulations—have raised the operational and compliance bar for all suppliers, whether in-house or contracted.
This environment has forced CDMOs and their clients to abandon single-source dependency. Dual sourcing, second-site qualification, and scenario-based contingency planning are no longer optional risk-management tools—they are now baseline expectations. The shift reflects a broader recognition that geopolitical risk is not a temporary headwind but a structural feature of 21st-century pharmaceutical manufacturing.
Structural Impact
Vendor Selection & Capacity Allocation
The geopolitical reorientation is reshaping how procurement teams evaluate CDMO partners. Historically, vendor selection prioritized cost per kilogram and regulatory track record. Today, geographic diversification and supply-chain resilience have become co-equal selection criteria.
CDMOs are mitigating geopolitical risks through dual sourcing, second-site qualification, and robust business continuity. This means procurement leaders must now assess not only a CDMO's technical capability but also its global footprint, regulatory standing in multiple jurisdictions, and ability to execute rapid site transfers if primary capacity becomes unavailable. A CDMO with manufacturing in a single geography—even if cost-competitive—now carries elevated risk premium in vendor scorecards.
The implication is capacity fragmentation. Rather than consolidating API production at one high-volume site, companies are splitting batch allocations across two or more CDMOs, often in different regions. This increases per-unit manufacturing cost (loss of economies of scale, duplicated validation work, higher logistics overhead) but reduces single-point-of-failure exposure. For large-volume or long-lifecycle products, in-house manufacturing offers deep oversight of quality, intellectual property, and long-term supply security, making the make-versus-buy decision increasingly favorable toward internal capacity for strategic molecules.
Compliance & Regulatory Readiness
Geopolitical fragmentation intersects with regulatory complexity. Serialization mandates, falsified medicines directives, and evolving Asia regulations create a patchwork of compliance requirements that vary by region. A CDMO operating in the U.S., EU, and India must maintain separate quality systems and documentation trails for each market, increasing operational overhead.
This regulatory burden disproportionately affects smaller CDMOs and those with limited geographic reach. Larger, multi-site CDMOs with established regulatory relationships in key markets can absorb these costs more easily. As a result, procurement teams face a paradox: while dual sourcing requires working with multiple CDMOs, the compliance burden favors consolidation with larger, more globally integrated partners. Resolving this tension often means selecting one large CDMO as primary supplier and a smaller, specialized CDMO as secondary backup—a hybrid model that balances resilience with operational efficiency.
Investment & Capacity Constraints
A secondary but critical threat looms: sustained reduction in drug development investment. If funding from private and public sources tightens, CDMO capacity utilization will decline, potentially forcing consolidation or exit among smaller players. This paradoxically increases concentration risk—fewer CDMOs available to serve as secondary suppliers—even as geopolitical risk demands more distributed sourcing.
Procurement teams must therefore monitor CDMO financial health and investment trends closely. A CDMO with strong balance-sheet backing and recent capacity expansion is more likely to remain viable as a long-term dual-source partner than one dependent on project-by-project revenue.
Strategic Blueprint
1. Audit & Map Your API Supply Chain
Begin with a granular supply-chain map: identify every API, its current CDMO(s), manufacturing location(s), and regulatory approvals. Flag single-source dependencies and assess geopolitical risk by region. Use geopolitical risk planning with flexible global footprints and scenario-based contingency models as your framework. For each critical API, define trigger points (e.g., trade sanctions, regulatory action, capacity loss) that would activate contingency sourcing.
2. Establish Dual-Source Qualification Roadmaps
For strategic APIs, initiate second-site qualification now. This is not a quick process—regulatory approval of a second manufacturing site typically requires 12–18 months of validation, stability data, and regulatory review. Waiting until a crisis occurs is too late. Prioritize APIs with the longest lead times, highest volumes, or greatest geopolitical exposure (e.g., APIs sourced from China or India, or dependent on raw materials from geopolitically sensitive regions).
When selecting a secondary CDMO, balance geographic diversification with regulatory alignment. A secondary site in a different region (e.g., EU or North America) reduces geopolitical concentration but may introduce new regulatory complexity. Ensure the secondary CDMO has demonstrated capability in robust business continuity planning and can scale rapidly if needed.
3. Evaluate Make-Versus-Buy for Strategic Molecules
For long-lifecycle, high-volume products, revisit the make-versus-buy decision. In-house API manufacturing offers deep oversight of quality, intellectual property, and long-term supply security, and can be justified on risk grounds alone, even if per-unit cost is higher than outsourced alternatives. This is particularly relevant for molecules with limited CDMO alternatives or those subject to geopolitical supply constraints.
However, in-house manufacturing requires sustained capital investment and technical expertise. For smaller companies or those with diverse API portfolios, selective internalization (e.g., in-house for 2–3 strategic APIs, outsourced for the rest) may be optimal.
4. Implement Agile Demand Forecasting & Inventory Buffers
Smaller players can gain competitive ground through lean, agile sourcing models, just-in-time partnerships with CDMOs, and advanced demand forecasting. However, "just-in-time" must be balanced against geopolitical risk. Consider strategic inventory buffers for critical APIs—not the pre-pandemic model of excess inventory, but targeted safety stock sized to cover 60–90 days of supply disruption.
Use advanced demand forecasting to optimize buffer levels and minimize carrying costs. This requires integration between commercial (demand planning), supply chain, and manufacturing teams.
5. Strengthen CDMO Partnerships & Transparency
Dual sourcing is only effective if both CDMOs maintain active, engaged relationships with your company. Avoid the trap of treating the secondary CDMO as a "backup" that receives minimal engagement. Instead, allocate a meaningful percentage of production (e.g., 30–40%) to the secondary site to keep their team sharp and ensure they can scale rapidly if needed.
Establish transparent, scenario-based contingency agreements with both CDMOs. Define what happens if primary capacity is lost, how quickly secondary capacity can ramp, and what cost adjustments apply. Clarity upfront prevents disputes during a crisis.
6. Monitor Regulatory & Geopolitical Developments
Stay informed on regulatory changes (e.g., new serialization requirements, regional API sourcing incentives) and geopolitical developments (e.g., trade tensions, sanctions, supply-chain regionalization). Subscribe to regulatory intelligence services and maintain relationships with industry associations and CDMO partners who can provide early warning of emerging risks.
Sources
- What matters in the API market as 2026 approaches — Pharmaceutical Technology
- What do you see as the biggest threat to the CDMO industry in 2026 or beyond? — Pharma's Almanac
- API Manufacturing: Key Trends Reshaping the Global Market — Contract Pharma
- Navigating Pharmaceutical Supply Chain Challenges: 2026 Risk Mitigation Strategies for Biotech Innovators — DES Pharma